Alenka Gagro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alenka Gagro has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
- Marija Jelusic
Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
15 shared publications - Marijan Frkovic
Department of Pediatrics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, 10000 Zagreb, Croatia
14 shared publications - Mario Sestan
Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
13 shared publications - Sasa Srsen
Department of Pediatrics, University of Split School of Medicine, University Hospital Centre Split, 21000 Split, Croatia
13 shared publications - Nastasia Kifer
Division of Rheumatology and Immunology, Department of Pediatrics, Referral Centre for Pediatric and Adolescent Rheumatology Republic of Croatia, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia 1
11 shared publications - Martina Held
University Hospital Centre Zagreb, Department of Paediatrics, University of Zagreb School of Medicine
10 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Croatian Medical Association in Paediatria Croatica
- Vol. 70 (suppl 6) , 37-38
Dugoročni ishodi juvenilnog idiopatskog artritisa
Juvenilni idiopatski artritis (JIA) najčešća je reumatska bolest koja obuhvaća heterogenu skupinu kroničnih artritisa koji započinju prije 16. godine života, traju najmanje šest tjedana i čija je etiologija još uvijek nepotpuno razjašnjena (1). JIA najčešće započinje u predškolskoj dobi, s različitom incidencijom među skupinama, a dvostruko je češći u djevojčica (2). Međunarodna liga reumatoloških udruženja (ILAR, engl. International League of Associations for Rheumatology) 1997. godine preporučila je klasifikaciju JIA-e prema obilježjima prisutnima tijekom prvih šest mjeseci bolesti u sedam skupina: sistemski JIA (sJIA, Stillova bolest), oligoartikularni JIA (oJIA), poliartikularni JIA s pozitivnim reumatoidnim faktorom (pJIA RF+), poliartikularni JIA s negativnim reumatoidnim faktorom (pJIA RF−), psorijatični artritis (jPsA), entezitisu pridruženi artritis (ERA, engl. enthesitis-related arthritis) i nediferencinirani artritis. Nove spoznaje o etiopatogenezi JIA-e pridonijele su razumijevanju početne prezentacije bolesti i njezina kliničkog tijeka, potaknule raspravu o novoj klasifikaciji te dovele do razvoja novih terapija (bioloških lijekova i inhibitora JAK-a) (2). Težina i klinički tijek JIA-e nepredvidivi su, uz različite stope remisije i razdoblja niske aktivnosti bolesti nakon kojih može nastupiti pogoršanje, tijekom liječenja ili nakon njegova prekida, kao i promjena vrste JIA-e tijekom života. Sve je više dokaza da rano liječenje usmjereno na postizanje terapijskog cilja (engl. treat to target) mijenja prognozu JIA-e. Međutim, više od 50 % bolesnika ima recidiv unutar 12 mjeseci od prekida biološke terapije, a aktivna bolest zabilježena je u 37–63 % odraslih bolesnika s JIA-om (3, 5, 6). Brojne su varijable istraživane radi predviđanja ishoda JIA-e, uključujući obilježja bolesnika i bolesti te rezultate slikovnih i laboratorijskih pretraga. Lošija prognoza JIA-e povezuje se sa simetričnim artritisom te artritisom određenih zglobova (gležnjeva, zapešća, prstiju i vratne kralježnice). Budući da je zahvaćenost zglobova povezana s aktivnošću bolesti, kao i sa skupinom JIA-e, teško je odrediti prognostičku vrijednost tih varijabli. Tako se, primjerice, smatra da djeca s oJIA-om imaju bolje ishode od djece s pJIA-om i ERA-om, no oko 50 % te djece nije u remisiji pet godina nakon postavljanja dijagnoze. Prediktor oštećenja također je prisutnost protutijela poput anti-CCP-a i RF-a (4). Utvrđivanje prediktora odgovora na specifične terapije također se pokazalo izazovnim. Proteinski biomarkeri koji omogućuju prepoznavanje bolesnika sa subkliničkom upalom mogli bi spriječiti prerano smanjivanje doze i ukidanje lijeka te omogućiti pravilno odlučivanje radi postizanja remisije bez lijekova. Najčešće proučavan biomarker jest serumski kalprotektin, za koji je pokazano da su povišene koncentracije prije prekida liječenja metotreksatom povezane s recidivom JIA-e. Genetski biomarkeri, osobito određeni polimorfizmi pojedinačnih nukleotida, povezani su s odgovorom na liječenje metotreksatom. Povišene koncentracije drugih biomarkera, poput interleukina 18 u sJIA-i i čimbenika rasta vaskularnog endotela, također su povezane s većom vjerojatnošću recidiva nakon ukidanja lijekova (2). Na ishode JIA-e utječu i komorbiditeti, definirani kao zasebni poremećaji dijagnosticirani prije ili tijekom JIA-e. Mogu biti povezani sa samom bolešću (npr. uveitis, najčešće u oJIA-i s pozitivnim antinuklearnim protutijelima; Crohnova bolest u bolesnika s ERA-om koji su HLA-B27 pozitivni; sindrom aktivacije makrofaga u sJIA-i) ili s liječenjem (infekcije). Dosadašnje dugoročne studije djece s JIA-om pokazale su povećan rizik od razvoja limfoproliferativnih bolesti, što se povezuje s kroničnom upalom i produljenom izloženošću imunosupresivnim terapijama. Važno je istaknuti da, unatoč povećanoj uporabi bioloških lijekova, nema dokaza o povećanom riziku od malignih bolesti u bolesnika s JIA-om do 18. godine života, no nužno je njihovo praćenje i tijekom odrasle dobi kako bi se ti podatci potvrdili (4). Iako svjedočimo napretku u liječenju bolesnika s JIA-om, i dalje postoje brojni izazovi povezani s poboljšanjem dugoročnih ishoda. Među njima su bolja klasifikacija JIA-e, prijelaz u skrb za odrasle, kvaliteta života, psihosocijalna potpora, otkrivanje osjetljivijih i specifičnijih biomarkera progresije bolesti i odgovora na liječenje te dugoročne longitudinalne studije kohorti bolesnika s JIA-om čija je bolest započela u eri biološke terapije.
- 14 November 2026
- Published by Croatian Medical Association in Paediatria Croatica
- Vol. 70 (suppl 6) , 37-38
Open AccessDugoročni ishodi juvenilnog idiopatskog artritisa
Juvenilni idiopatski artritis (JIA) najčešća je reumatska bolest koja obuhvaća heterogenu skupinu kroničnih artritisa koji započinju prije 16. godine života, traju najmanje šest tjedana i čija je etiologija još uvijek nepotpuno razjašnjena (1). JIA najčešće započinje u predškolskoj dobi, s različitom incidencijom među skupinama, a dvostruko je češći u djevojčica (2). Međunarodna liga reumatoloških udruženja (ILAR, engl. International League of Associations for Rheumatology) 1997. godine preporučila je klasifikaciju JIA-e prema obilježjima prisutnima tijekom prvih šest mjeseci bolesti u sedam skupina: sistemski JIA (sJIA, Stillova bolest), oligoartikularni JIA (oJIA), poliartikularni JIA s pozitivnim reumatoidnim faktorom (pJIA RF+), poliartikularni JIA s negativnim reumatoidnim faktorom (pJIA RF−), psorijatični artritis (jPsA), entezitisu pridruženi artritis (ERA, engl. enthesitis-related arthritis) i nediferencinirani artritis. Nove spoznaje o etiopatogenezi JIA-e pridonijele su razumijevanju početne prezentacije bolesti i njezina kliničkog tijeka, potaknule raspravu o novoj klasifikaciji te dovele do razvoja novih terapija (bioloških lijekova i inhibitora JAK-a) (2). Težina i klinički tijek JIA-e nepredvidivi su, uz različite stope remisije i razdoblja niske aktivnosti bolesti nakon kojih može nastupiti pogoršanje, tijekom liječenja ili nakon njegova prekida, kao i promjena vrste JIA-e tijekom života. Sve je više dokaza da rano liječenje usmjereno na postizanje terapijskog cilja (engl. treat to target) mijenja prognozu JIA-e. Međutim, više od 50 % bolesnika ima recidiv unutar 12 mjeseci od prekida biološke terapije, a aktivna bolest zabilježena je u 37–63 % odraslih bolesnika s JIA-om (3, 5, 6). Brojne su varijable istraživane radi predviđanja ishoda JIA-e, uključujući obilježja bolesnika i bolesti te rezultate slikovnih i laboratorijskih pretraga. Lošija prognoza JIA-e povezuje se sa simetričnim artritisom te artritisom određenih zglobova (gležnjeva, zapešća, prstiju i vratne kralježnice). Budući da je zahvaćenost zglobova povezana s aktivnošću bolesti, kao i sa skupinom JIA-e, teško je odrediti prognostičku vrijednost tih varijabli. Tako se, primjerice, smatra da djeca s oJIA-om imaju bolje ishode od djece s pJIA-om i ERA-om, no oko 50 % te djece nije u remisiji pet godina nakon postavljanja dijagnoze. Prediktor oštećenja također je prisutnost protutijela poput anti-CCP-a i RF-a (4). Utvrđivanje prediktora odgovora na specifične terapije također se pokazalo izazovnim. Proteinski biomarkeri koji omogućuju prepoznavanje bolesnika sa subkliničkom upalom mogli bi spriječiti prerano smanjivanje doze i ukidanje lijeka te omogućiti pravilno odlučivanje radi postizanja remisije bez lijekova. Najčešće proučavan biomarker jest serumski kalprotektin, za koji je pokazano da su povišene koncentracije prije prekida liječenja metotreksatom povezane s recidivom JIA-e. Genetski biomarkeri, osobito određeni polimorfizmi pojedinačnih nukleotida, povezani su s odgovorom na liječenje metotreksatom. Povišene koncentracije drugih biomarkera, poput interleukina 18 u sJIA-i i čimbenika rasta vaskularnog endotela, također su povezane s većom vjerojatnošću recidiva nakon ukidanja lijekova (2). Na ishode JIA-e utječu i komorbiditeti, definirani kao zasebni poremećaji dijagnosticirani prije ili tijekom JIA-e. Mogu biti povezani sa samom bolešću (npr. uveitis, najčešće u oJIA-i s pozitivnim antinuklearnim protutijelima; Crohnova bolest u bolesnika s ERA-om koji su HLA-B27 pozitivni; sindrom aktivacije makrofaga u sJIA-i) ili s liječenjem (infekcije). Dosadašnje dugoročne studije djece s JIA-om pokazale su povećan rizik od razvoja limfoproliferativnih bolesti, što se povezuje s kroničnom upalom i produljenom izloženošću imunosupresivnim terapijama. Važno je istaknuti da, unatoč povećanoj uporabi bioloških lijekova, nema dokaza o povećanom riziku od malignih bolesti u bolesnika s JIA-om do 18. godine života, no nužno je njihovo praćenje i tijekom odrasle dobi kako bi se ti podatci potvrdili (4). Iako svjedočimo napretku u liječenju bolesnika s JIA-om, i dalje postoje brojni izazovi povezani s poboljšanjem dugoročnih ishoda. Među njima su bolja klasifikacija JIA-e, prijelaz u skrb za odrasle, kvaliteta života, psihosocijalna potpora, otkrivanje osjetljivijih i specifičnijih biomarkera progresije bolesti i odgovora na liječenje te dugoročne longitudinalne studije kohorti bolesnika s JIA-om čija je bolest započela u eri biološke terapije.
- Open Access
- 1 June 2026
- Published by Croatian Medical Association in Paediatria Croatica
- Vol. 70 (2) , 95-111
When should an inborn error of immunity be suspected?
Inborn errors of immunity represent a heterogeneous group of monogenic hereditary disorders resulting from impaired development or function of the immune system. Although rare as individual entities, their cumulative prevalence is estimated at 1:1,000 to 1:5,000. Clinically, these conditions are characterized by severe, recurrent, and antibiotic-resistant infections, frequently involving opportunistic pathogens. The incidence and spectrum of such infections are influenced by exposure to pathogens, which is shaped by factors such as universal vaccination programs and global health events, including the recent coronavirus disease pandemic. Beyond infectious complications, affected individuals frequently present with non-infectious manifestations, such as autoimmune, autoinflammatory, allergic, and malignant disorders, therefore broadening the clinical phenotype. Recognition of warning signs of inborn errors of the immune system is essential for pediatric healthcare providers, who are often the first to initiate immunological evaluation. Upon establishing clinical and laboratory suspicion, timely referral to tertiary centers is warranted. Early diagnosis and targeted intervention significantly reduce morbidity and complications and improve treatment outcomes in patients with congenital immunodeficiencies.
- 1 June 2026
- Published by Croatian Medical Association in Paediatria Croatica
- Vol. 70 (2) , 95-111
Open AccessWhen should an inborn error of immunity be suspected?
Inborn errors of immunity represent a heterogeneous group of monogenic hereditary disorders resulting from impaired development or function of the immune system. Although rare as individual entities, their cumulative prevalence is estimated at 1:1,000 to 1:5,000. Clinically, these conditions are characterized by severe, recurrent, and antibiotic-resistant infections, frequently involving opportunistic pathogens. The incidence and spectrum of such infections are influenced by exposure to pathogens, which is shaped by factors such as universal vaccination programs and global health events, including the recent coronavirus disease pandemic. Beyond infectious complications, affected individuals frequently present with non-infectious manifestations, such as autoimmune, autoinflammatory, allergic, and malignant disorders, therefore broadening the clinical phenotype. Recognition of warning signs of inborn errors of the immune system is essential for pediatric healthcare providers, who are often the first to initiate immunological evaluation. Upon establishing clinical and laboratory suspicion, timely referral to tertiary centers is warranted. Early diagnosis and targeted intervention significantly reduce morbidity and complications and improve treatment outcomes in patients with congenital immunodeficiencies.
- Open Access
- 16 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7777
Association of Glutathione Transferase M1, T1, P1 and A1 Gene Polymorphism and Susceptibility to IgA Vasculitis
Endothelial cell injury is a hallmark of IgA vasculitis (IgAV), possibly associated with various factors, including oxidative stress. Certain single nucleotide polymorphisms (SNPs) of glutathione S-transferases (GST) genes have been shown to increase susceptibility to oxidative stress. The objective of our study was to evaluate the gene polymorphisms of GSTM1, GSTT1, GSTP1, and GSTA1 in patients with IgAV. DNA was extracted from the blood of 124 children with IgAV and 168 age-matched healthy controls. A higher frequency of the GSTM1 null genotype was observed in patients with gastrointestinal (GI) system involvement compared to those without GI system involvement (51.5% vs. 28.6%, p = 0.011). Additionally, the GSTM1 null genotype was less prevalent (30.8% vs. 69.2%, p = 0.032), while the GSTP1 Val/Val genotype was significantly more prevalent in patients who developed urogenital complications (scrotal swelling) during the course of the disease (60% vs. 40%, p = 0.039). This study is the first to suggest an association between GSTM1 and GSTP1 polymorphisms and various phenotypes observed during the clinical course of IgAV in the pediatric population. However, it was performed on a national and likely single ethnic cohort, too small for definitive conclusions, so larger studies are needed to confirm this association.
- 16 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7777
Open AccessAssociation of Glutathione Transferase M1, T1, P1 and A1 Gene Polymorphism and Susceptibility to IgA Vasculitis
Endothelial cell injury is a hallmark of IgA vasculitis (IgAV), possibly associated with various factors, including oxidative stress. Certain single nucleotide polymorphisms (SNPs) of glutathione S-transferases (GST) genes have been shown to increase susceptibility to oxidative stress. The objective of our study was to evaluate the gene polymorphisms of GSTM1, GSTT1, GSTP1, and GSTA1 in patients with IgAV. DNA was extracted from the blood of 124 children with IgAV and 168 age-matched healthy controls. A higher frequency of the GSTM1 null genotype was observed in patients with gastrointestinal (GI) system involvement compared to those without GI system involvement (51.5% vs. 28.6%, p = 0.011). Additionally, the GSTM1 null genotype was less prevalent (30.8% vs. 69.2%, p = 0.032), while the GSTP1 Val/Val genotype was significantly more prevalent in patients who developed urogenital complications (scrotal swelling) during the course of the disease (60% vs. 40%, p = 0.039). This study is the first to suggest an association between GSTM1 and GSTP1 polymorphisms and various phenotypes observed during the clinical course of IgAV in the pediatric population. However, it was performed on a national and likely single ethnic cohort, too small for definitive conclusions, so larger studies are needed to confirm this association.
- Open Access
- 10 May 2024
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 62 (2) , 71-73
Usefulness of interleukin-1 blockade in autoinflammatory diseases
- 10 May 2024
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 62 (2) , 71-73
Open AccessUsefulness of interleukin-1 blockade in autoinflammatory diseases
- Open Access
- 16 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (8) , 4383
Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV)
The pathogenesis of IgAV, the most common systemic vasculitis in childhood, appears to be complex and requires further elucidation. We aimed to investigate the potential role of galactose-deficient immunoglobulin A1 (Gd-IgA1), high-mobility group box 1 (HMGB1), receptor for advanced glycation end products (RAGE) and protocadherin 1 (PCDH1) in the pathogenesis of IgAV. Our prospective study enrolled 86 patients with IgAV and 70 controls. HMGB1, RAGE, Gd-IgA1 and PCDH1 in serum and urine were determined by the enzyme-linked immunosorbent assay (ELISA) method at the onset of the disease and after a six-month interval in patients and once in the control group. Serum concentrations of HMGB1, RAGE and PCDH1 and urinary concentrations of HMGB1, RAGE, Gd-IgA1 and PCDH1 were significantly higher in patients with IgAV than in the control group (p < 0.001). Concentrations of HMGB1 (5573 pg/mL vs. 3477 pg/mL vs. 1088 pg/mL, p < 0.001) and RAGE (309 pg/mL vs. 302.4 pg/mL vs. 201.3 pg/mL, p = 0.012) in the serum of patients remained significantly elevated when the disease onset was compared with the six-month follow-up interval, and thus could be a potential marker of disease activity. Urinary concentration of HMGB1 measured in the follow-up period was higher in patients with nephritis compared to IgAV without nephritis (270.9 (146.7–542.7) ng/mmol vs. 133.2 (85.9–318.6) ng/mmol, p = 0.049) and significantly positively correlated with the urine albumine to creatinine ratio (τ = 0.184, p < 0.05), the number of erythrocytes in urine samples (τ = 0.193, p < 0.05) and with the outcome of nephritis (τ = 0.287, p < 0.05); therefore, HMGB1 could be a potential tool for monitoring patients with IgAV who develop nephritis. Taken together, our results imply a possible interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in the development of IgAV. The identification of sensitive biomarkers in IgAV may provide disease prevention and future therapeutics.
- 16 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (8) , 4383
Open AccessInsight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV)
The pathogenesis of IgAV, the most common systemic vasculitis in childhood, appears to be complex and requires further elucidation. We aimed to investigate the potential role of galactose-deficient immunoglobulin A1 (Gd-IgA1), high-mobility group box 1 (HMGB1), receptor for advanced glycation end products (RAGE) and protocadherin 1 (PCDH1) in the pathogenesis of IgAV. Our prospective study enrolled 86 patients with IgAV and 70 controls. HMGB1, RAGE, Gd-IgA1 and PCDH1 in serum and urine were determined by the enzyme-linked immunosorbent assay (ELISA) method at the onset of the disease and after a six-month interval in patients and once in the control group. Serum concentrations of HMGB1, RAGE and PCDH1 and urinary concentrations of HMGB1, RAGE, Gd-IgA1 and PCDH1 were significantly higher in patients with IgAV than in the control group (p < 0.001). Concentrations of HMGB1 (5573 pg/mL vs. 3477 pg/mL vs. 1088 pg/mL, p < 0.001) and RAGE (309 pg/mL vs. 302.4 pg/mL vs. 201.3 pg/mL, p = 0.012) in the serum of patients remained significantly elevated when the disease onset was compared with the six-month follow-up interval, and thus could be a potential marker of disease activity. Urinary concentration of HMGB1 measured in the follow-up period was higher in patients with nephritis compared to IgAV without nephritis (270.9 (146.7–542.7) ng/mmol vs. 133.2 (85.9–318.6) ng/mmol, p = 0.049) and significantly positively correlated with the urine albumine to creatinine ratio (τ = 0.184, p < 0.05), the number of erythrocytes in urine samples (τ = 0.193, p < 0.05) and with the outcome of nephritis (τ = 0.287, p < 0.05); therefore, HMGB1 could be a potential tool for monitoring patients with IgAV who develop nephritis. Taken together, our results imply a possible interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in the development of IgAV. The identification of sensitive biomarkers in IgAV may provide disease prevention and future therapeutics.
- Open Access
- 11 April 2024
- Published by Croatian Medical Association in Lijecnicki Vjesnik
- Vol. 146 (Supp 1) , 95-107
Development of the immune system and exposure to infections
Infekcije su jedan od prvih znakova za brojne prirođene poremećaje imunosti. U djece se infekcije vide češće, što najčešće objašnjavamo fiziološkom nezrelošću imunološkog sustava. Racionalna procjena u koje djece treba učiniti daljnja ispitivanja iza...
- 11 April 2024
- Published by Croatian Medical Association in Lijecnicki Vjesnik
- Vol. 146 (Supp 1) , 95-107
Open AccessDevelopment of the immune system and exposure to infections
Infekcije su jedan od prvih znakova za brojne prirođene poremećaje imunosti. U djece se infekcije vide češće, što najčešće objašnjavamo fiziološkom nezrelošću imunološkog sustava. Racionalna procjena u koje djece treba učiniti daljnja ispitivanja iza...
- Open Access
- 28 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3795
Erythrocyte Glutathione S-Transferase Activity as a Sensitive Marker of Kidney Function Impairment in Children with IgA Vasculitis
IgA vasculitis (IgAV) is the most common childhood vasculitis. The main cause of morbidity and mortality in children with IgAV is nephritis (IgAVN), but the risk of its development, severity, and chronicity remain unclear. Erythrocyte glutathione S-transferase (e-GST) activity has been previously detected as a sensitive marker of kidney function impairment in several diseases. We spectrophotometrically assessed and correlated e-GST activity between 55 IgAV patients without nephritis (IgAVwN), 42 IgAVN patients, and 52 healthy controls. At disease onset, e-GST activity was significantly higher in IgAVN patients (median (interquartile range)) (5.7 U/gHb (4.4–7.5)) than in IgAVwN patients (3.1 U/gHb (2.2–4.2); p < 0.001), and controls (3.1 U/gHb (1.9–4.2); p < 0.001). Therewithal, there were no differences between the IgAVwN patients and controls (p = 0.837). e-GST activity was also significantly higher in the IgAVN patients than in the IgAVwN patients after 3 months (5.0 U/gHb (4.2–6.2) vs. 3.3 U/gHb (2.3–4.1); p < 0.001) and 6 months (4.2 U/gHb (3.2–5.8) vs. 3.3 U/gHb (2.1–4.1); p < 0.001) since the disease onset. Consistent correlations between e-GST activity and serum creatinine, estimated glomerular filtration rate (eGFR), and proteinuria levels were not detected. In conclusion, increased e-GST activity can serve as a subtle indicator of kidney function impairment in children with IgAV.
- 28 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3795
Open AccessErythrocyte Glutathione S-Transferase Activity as a Sensitive Marker of Kidney Function Impairment in Children with IgA Vasculitis
IgA vasculitis (IgAV) is the most common childhood vasculitis. The main cause of morbidity and mortality in children with IgAV is nephritis (IgAVN), but the risk of its development, severity, and chronicity remain unclear. Erythrocyte glutathione S-transferase (e-GST) activity has been previously detected as a sensitive marker of kidney function impairment in several diseases. We spectrophotometrically assessed and correlated e-GST activity between 55 IgAV patients without nephritis (IgAVwN), 42 IgAVN patients, and 52 healthy controls. At disease onset, e-GST activity was significantly higher in IgAVN patients (median (interquartile range)) (5.7 U/gHb (4.4–7.5)) than in IgAVwN patients (3.1 U/gHb (2.2–4.2); p < 0.001), and controls (3.1 U/gHb (1.9–4.2); p < 0.001). Therewithal, there were no differences between the IgAVwN patients and controls (p = 0.837). e-GST activity was also significantly higher in the IgAVN patients than in the IgAVwN patients after 3 months (5.0 U/gHb (4.2–6.2) vs. 3.3 U/gHb (2.3–4.1); p < 0.001) and 6 months (4.2 U/gHb (3.2–5.8) vs. 3.3 U/gHb (2.1–4.1); p < 0.001) since the disease onset. Consistent correlations between e-GST activity and serum creatinine, estimated glomerular filtration rate (eGFR), and proteinuria levels were not detected. In conclusion, increased e-GST activity can serve as a subtle indicator of kidney function impairment in children with IgAV.
- Open Access
- 28 March 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 750
Serum Levels of S100A8/A9 as a Biomarker of Disease Activity in Patients with IgA Vasculitis
S100A8/A9 protein is a well-known marker of disease activity or severity in many autoimmune and autoinflammatory diseases, but there have not been many studies about the role of S100A8/A9 in IgA vasculitis (IgAV). The aim of our study was to evaluate S100A8/A9 as a possible biomarker of activity in IgAV. We measured the serum levels of S100A8/A9 in pediatric patients with IgA vasculitis at the onset of the disease, after three months, and after six months. We compared these levels between patients with active disease, remission, and a control group, and assessed their correlation with disease activity and other markers of inflammation. Patients with active disease had significantly higher levels of serum S100A8/A9 (median ± SD) than those in the control group at the beginning of the disease (5740 ± 3157 ng/mL vs. 1447 ± 858.3 ng/mL; p < 0.0001), but also three months and six months after disease onset (p < 0.001). There was a positive correlation between S100A8/A9 serum levels and disease activity (p = 0.0003). Patients with active disease had significantly higher levels of S100A8/A9 than those in remission three months after disease onset (p = 0.0260). There was a correlation between S100A8/A9 and C-reactive protein, the C3 component of complement, ferritin, and fibrinogen. Serum levels of S100A8/A9 were also higher in patients with greater skin areas covered with rash. We demonstrated that serum levels of S100A8/A9 correlated well with disease activity and other biomarkers of inflammation in children with IgAV. According to our results, serum S100A8/A9 may be a good indicator of active disease in IgAV.
- 28 March 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 750
Open AccessSerum Levels of S100A8/A9 as a Biomarker of Disease Activity in Patients with IgA Vasculitis
S100A8/A9 protein is a well-known marker of disease activity or severity in many autoimmune and autoinflammatory diseases, but there have not been many studies about the role of S100A8/A9 in IgA vasculitis (IgAV). The aim of our study was to evaluate S100A8/A9 as a possible biomarker of activity in IgAV. We measured the serum levels of S100A8/A9 in pediatric patients with IgA vasculitis at the onset of the disease, after three months, and after six months. We compared these levels between patients with active disease, remission, and a control group, and assessed their correlation with disease activity and other markers of inflammation. Patients with active disease had significantly higher levels of serum S100A8/A9 (median ± SD) than those in the control group at the beginning of the disease (5740 ± 3157 ng/mL vs. 1447 ± 858.3 ng/mL; p < 0.0001), but also three months and six months after disease onset (p < 0.001). There was a positive correlation between S100A8/A9 serum levels and disease activity (p = 0.0003). Patients with active disease had significantly higher levels of S100A8/A9 than those in remission three months after disease onset (p = 0.0260). There was a correlation between S100A8/A9 and C-reactive protein, the C3 component of complement, ferritin, and fibrinogen. Serum levels of S100A8/A9 were also higher in patients with greater skin areas covered with rash. We demonstrated that serum levels of S100A8/A9 correlated well with disease activity and other biomarkers of inflammation in children with IgAV. According to our results, serum S100A8/A9 may be a good indicator of active disease in IgAV.
- Open Access
- 13 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2253
Involvement of M1-Activated Macrophages and Perforin/Granulysin Expressing Lymphocytes in IgA Vasculitis Nephritis
We investigated the polarisation of CD68+ macrophages and perforin and granulysin distributions in kidney lymphocyte subsets of children with IgA vasculitis nephritis (IgAVN). Pro-inflammatory macrophage (M)1 (CD68/iNOS) or regulatory M2 (CD68/arginase-1) polarisation; spatial arrangement of macrophages and lymphocytes; and perforin and granulysin distribution in CD3+ and CD56+ cells were visulaised using double-labelled immunofluorescence. In contrast to the tubules, iNOS+ cells were more abundant than the arginase-1+ cells in the glomeruli. CD68+ macrophage numbers fluctuated in the glomeruli and were mostly labelled with iNOS. CD68+/arginase-1+ cells are abundant in the tubules. CD56+ cells, enclosed by CD68+ cells, were more abundant in the glomeruli than in the tubuli, and co-expressed NKp44. The glomerular and interstitial/intratubular CD56+ cells express perforin and granulysin, respectively. The CD3+ cells did not express perforin, while a minority expressed granulysin. Innate immunity, represented by M1 macrophages and CD56+ cells rich in perforin and granulysin, plays a pivotal role in the acute phase of IgAVN.
- 13 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2253
Open AccessInvolvement of M1-Activated Macrophages and Perforin/Granulysin Expressing Lymphocytes in IgA Vasculitis Nephritis
We investigated the polarisation of CD68+ macrophages and perforin and granulysin distributions in kidney lymphocyte subsets of children with IgA vasculitis nephritis (IgAVN). Pro-inflammatory macrophage (M)1 (CD68/iNOS) or regulatory M2 (CD68/arginase-1) polarisation; spatial arrangement of macrophages and lymphocytes; and perforin and granulysin distribution in CD3+ and CD56+ cells were visulaised using double-labelled immunofluorescence. In contrast to the tubules, iNOS+ cells were more abundant than the arginase-1+ cells in the glomeruli. CD68+ macrophage numbers fluctuated in the glomeruli and were mostly labelled with iNOS. CD68+/arginase-1+ cells are abundant in the tubules. CD56+ cells, enclosed by CD68+ cells, were more abundant in the glomeruli than in the tubuli, and co-expressed NKp44. The glomerular and interstitial/intratubular CD56+ cells express perforin and granulysin, respectively. The CD3+ cells did not express perforin, while a minority expressed granulysin. Innate immunity, represented by M1 macrophages and CD56+ cells rich in perforin and granulysin, plays a pivotal role in the acute phase of IgAVN.
- Open Access
- 10 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 882
HLA Polymorphisms and Clinical Manifestations in IgA Vasculitis
Studies concerning the genetic background of IgA vasculitis (IgAV), a small-vessel vasculitis occurring predominantly in childhood, have confirmed that the HLA-DRB1 gene showed a strong association with disease susceptibility. The objective was to investigate human leukocyte antigen (HLA) polymorphisms among Croatian patients with IgAV and their influence on disease susceptibility and clinical heterogeneity. Thus, 130 children with IgAV and 202 unrelated healthy individuals were enrolled in the study. Genomic DNA was extracted from whole peripheral blood, and HLA-A, -B, -DRB1 and -DQB1 gene polymorphism analysis was performed. HLA-A*03 (21.4% vs. 12.38%, p = 0.0092), HLA-B*37 (2.9% vs. 0.2%, p = 0.0054) and HLA-DRB1*12 (3.1% vs. 0.7%, p = 0.0216) alleles were significantly more frequent in IgAV patients than in controls. High-resolution typing revealed significantly higher frequency of HLA-DRB1*10:01 and -DRB1*11:03 among IgAV patients with gastrointestinal manifestations of the disease in comparison to controls (p = 0.0021 and p = 0.0301, respectively), while HLA-DRB1*14:01P occurred significantly more often in the group of patients who developed nephritis during the course of the disease (17.5% vs. 4.5%, p = 0.0006). Our results demonstrated that there is an association of HLA-A*03, HLA-B*37 and HLA-DRB1*12 alleles with susceptibility to IgAV in the examined Croatian pediatric population. Studies which aim to determine the HLA profile may contribute to the elucidation of the genetic background of autoimmune diseases, including IgAV.
- 10 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 882
Open AccessHLA Polymorphisms and Clinical Manifestations in IgA Vasculitis
Studies concerning the genetic background of IgA vasculitis (IgAV), a small-vessel vasculitis occurring predominantly in childhood, have confirmed that the HLA-DRB1 gene showed a strong association with disease susceptibility. The objective was to investigate human leukocyte antigen (HLA) polymorphisms among Croatian patients with IgAV and their influence on disease susceptibility and clinical heterogeneity. Thus, 130 children with IgAV and 202 unrelated healthy individuals were enrolled in the study. Genomic DNA was extracted from whole peripheral blood, and HLA-A, -B, -DRB1 and -DQB1 gene polymorphism analysis was performed. HLA-A*03 (21.4% vs. 12.38%, p = 0.0092), HLA-B*37 (2.9% vs. 0.2%, p = 0.0054) and HLA-DRB1*12 (3.1% vs. 0.7%, p = 0.0216) alleles were significantly more frequent in IgAV patients than in controls. High-resolution typing revealed significantly higher frequency of HLA-DRB1*10:01 and -DRB1*11:03 among IgAV patients with gastrointestinal manifestations of the disease in comparison to controls (p = 0.0021 and p = 0.0301, respectively), while HLA-DRB1*14:01P occurred significantly more often in the group of patients who developed nephritis during the course of the disease (17.5% vs. 4.5%, p = 0.0006). Our results demonstrated that there is an association of HLA-A*03, HLA-B*37 and HLA-DRB1*12 alleles with susceptibility to IgAV in the examined Croatian pediatric population. Studies which aim to determine the HLA profile may contribute to the elucidation of the genetic background of autoimmune diseases, including IgAV.